Central Drugs Standard Control Organisation (CDSCO) nods to Minoxidil topical solution in India.
Dr. Reddy’s announced the launch of Minoxidil topical solution for female pattern hair loss (FPHL).
On September 7, 2021, Dr. Reddy’s Laboratories announced the launch of a prescription medicine namely Minoxidil topical solution USP 2% and 5% for the treatment of female pattern hair loss (FPHL) following its first-ever approval by the Central Drugs Standard Control Organisation (CDSCO) in India.
While Minoxidil topical solution was primarily approved for male pattern hair loss (alopecia), this new indication gets added to the drug. Other than Minoxidil, there are presently no drugs approved for FPHL treatment in the country.
Dr. Reddy’s will be marketing the products Minoxidil topical solution USP 2% and 5% under the brand names Mintop 2% and Mintop Eva 5% respectively. Further, this medicine will be available in India as a first-line treatment option for women’s hair loss.
Female pattern hair loss or androgenetic alopecia is a condition associated with permanent hair loss (baldness) from the scalp in women. Up to two-thirds of women experience such a disease post-menopause. The hair loss pattern is quite similar to that of men as they both are characterized by a common genetic cause.
Minoxidil topical solution has been proved to be responsible for stimulating anagen growth. This will help reverse the hair loss process and stimulate the growth phase. This solution will be available on a valid prescription by a dermatologist.
Hyderabad-based Dr. Reddy’s Laboratories is a pharmaceutical pioneer founded by Dr. Anji Reddy. Its three major businesses are global generics, proprietary products, and pharmaceutical services & active ingredients.